Moderna posts bigger loss than expected
Julie Hyman and Josh Lipton preview the biggest earnings stories and economic data due out tomorrow, Friday, February 14. Pharmaceutical company Moderna (MRNA) and energy provider Enbridge (ENB) are ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
5h
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.
An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...
The study is continuing and Moderna anticipates final efficacy data later this year. See Also: Teva Pharmaceutical Stock Falls On Q4 Earnings: What’s Going On? Richter lowered the probability of ...
In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine in healthy adults aged 18 years and older. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback